Stroke Treatment with Tissue Plasminogen Activator in the Setting of Aortic Dissection
Neurol 54:1010, Fessler,A.J. & Alberts,M.J., 2000
Neurological Emergencies: Acute Stroke
JNNP 68:277-288, Davenport,R. & Dennis,M., 2000
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
JAMA 283:1145-1150,1189, Albers,G.W.,et al, 2000
Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke
JAMA 283:1151-1158,1189, Katzan,I.L.,et al, 2000
Managing Women With Epilepsy
BMJ 320:3-4, Wiebe,S., 2000
The Central Nervous system and Infection by Candida Species
Diagn Microbial Infect Dis 37:169-179, Sanchez-Portocarrero, J.,et al, 2000
Fungal Meningitis
Semin Neurol 20:307-322, Gottfredsson, M. & Perfect J.R., 2000
Topiramate in Clinical Practice:First Year's Postlicensing Experience in a Specialist Epilepsy Clinic
JNNP 66:759-763, Kellett,M.W.,et al, 1999
Initial Clinical Experience with IV Tissue Plasminogen Activator for Acute Ischemic Stroke:A Multicenter Survey
Neurol 53:424-427, Tanne,D.,et al, 1999
Lamotrigine Adjunctive Therapy in painful Phenomena in MS:Preliminary Observations
Neurol 53:433, Cianchetti,C.,et al, 1999
Consent Issues in the Management of Cerebrovascular Diseases, A Position Paper of the American Academy of Neurology Ethics and Humanities Subcommittee
Neurol 53:9-11, , 1999
Topiramate-Treated Cluster Headache
Neurol 53:234-236, Wheeler,S.D.&Carrazana,E.J., 1999
Seizure Control and Mortality in Epilepsy
Ann Neurol 46:45-50, Sperling,M.R.,et al, 1999
Cognitive Effects of Topiramate,Gabapentin,And Lamotrigine in Healthy Young Adults
Neurol 52:321-327, Martin,R.,et al, 1999
Safety and Efficacy of Vigabatrin and Carbamazepine in Newly Diagnosed epilepsy:A Multicentre Randomised Double-Blind Study
Lancet 354:13-19, Chadwick,D., 1999
Seizure Frequency and the Health-Related Quality of Life of Adults with epilepsy
Neurol 53:162-166, Leidy,N.K.,et al, 1999
Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis During First Weeks of Antiepileptic Therapy:A Case-Control Study
Lancet 353:2190-2194, Rzany,B.,et al, 1999
Intraarterial Thrombolysis for Treatment of Acute Stroke:Experience in 26 Patients with Long-Term Follow-Up
AJNR 20:1291-1299, 1194, Jahan,R.,et al, 1999
Demyelinative Brainstem Encephalitis Responsive to Intravenous Immunoglobulin Therapy
Pediatrics 104:301-304, Assa,A.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
Prevalence of Peripheral Neuropathy in Injection Drug Users
Neurol 53:592-597, Berger,A.R.,et al, 1999
Agreement and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for Intravenous rtPA Therapy
Stroke 30:1528-1533, Grotta,J.C.,et al, 1999
Phenobarbital Compared with Phenytoin for the Treatment of Neonatal Seizures
NEJM 341:485-489, Painter,M.J.,et al, 1999
Getting Oriented to Patient-Oriented Outcomes
Neurol 53:662-663, Vickrey,B.G., 1999
Patient-Oriented Outcome Assessment After Temporal Lobectomy for Refractory Epilepsy
Neurol 53:687-694, 662, Gilliam,F.,et al, 1999
Reassessment:Vagus Nerve Stimulation for Epilepsy
Neurol 53:666-669, Fisher,R.S.&Handforth,A., 1999
Pompholyx (Vesicular Eczema) After IV Immunoglobulin Therapy for Neurologic Disease
Neurol 53:1154-1155, Iannaccone,S.,et al, 1999
When to Start and Stop Anticonvulsant Therapy in Children
Arch Neurol 56:1073-1077, Greenwood,R.S.&Tennison,M.B., 1999
Vigabatrin, a Gabaergic Antiepileptic Drug, Causes Concentric Visual Field Defects
Neurol 53:922-926, Kalviainen,R.,et al, 1999
Intra-Arterial Cerebral Thrombolysis for Acutre Ischemic Stroke in a Community Hospital
AJNR 20:1682-1687,1580, Edwards,M.T.,et al, 1999
Predictors of Clinical Improvement,Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke
Stroke 30:2094-2100, Suarez,J.I.,et al, 1999
Clinical Benefits of Donepezil:Results from a Long-Term Phase III Extension Trial
Neurol 52:A174, Doody,R.S.,et al, 1999
Multisystem Hypersensitivity Reaction to Lamotrigine
Neurol 53:1367, Sarris,B.M.&Wong,J.G., 1999
Therapeutic Plasma Exchange and Intravenous Immunoglobulin for Obsessive-Compulsive Disorder and Tic Disorders in Childhood
Lancet 354:1153-1158, Perlmutter,S.J.,et al, 1999
Expanding the Window for Thrombolytic Therapy in Acute Stroke, The Potential Role of Acute MRI for Patient Selection
Stroke 30:2230-2237, Albers,G.W., 1999
MRI Features of Intracerebral Hemorrhage Within 2 Hours from Symptom Onset
Stroke 30:2263-2267, Linfante,I.,et al, 1999
Antiepileptic Drug Regimens and Major Congenital Abnormalities in the Offspring
Ann Neurol 46:739-746, Samren,E.B.,et al, 1999
Intractable Seizures in Pregnancy
Lancet 354:1522, Smith,P.E.M.,et al, 1999
Sudden Unexpected Death in epilepsy (SUDEP): A Clinical Perspective and a Search for Risk Factors
JNNP 67:439-444,427, Kloster,R.&Engelskjon,T., 1999
Psychiatric Adverse Events During Vigabatrin Therapy
Neurol 53:1503-1511, Levinson,D.F.&Devinsky,O., 1999
Long-Term Treatment with Vagus Nerve Stimulation in Patients with Refractory Epilepsy
Neurol 53:1731-1735, Morris,G.L.,et al, 1999
Brief Antiepileptic Drug Withdrawal Prolongs Interval To Next Seizure
Neurol 53:1736-1741, Laowattana,S.,et al, 1999
The Intensive Care Management of Acute Ischemic Stroke
The Neurologist 5:313-325, Deibert,E.&Diringer,M.N., 1999
Intra-Arterial Prourokinase for Acute Ischemic Stroke, The PROACT II Study:A Randomized Controlled Trial
JAMA 282:2003-2011, Furlan,A.,et al, 1999
Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke, Emergency Management of Stroke (EMS) Bridging Trial
Stroke 30:2598-2605, Lewandowski,C.A.,et al, 1999
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset, The ATLANTIS Study:A Randomized Controlled Trial
JAMA 282:2019-2026, Clark,W.M.,et al, 1999
Diffuse Cerebral Vasculitis with Normal Results on Brain MR Imaging
AJR 173:1494-1496, Imbesi,S.G., 1999